These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7293030)

  • 21. [Hormone therapy in carcinoma of the prostate].
    Marberger H
    Wien Klin Wochenschr; 1966 Jul; 78(29):512-4 passim. PubMed ID: 5992834
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma testosterone in patients receiving diethylstilbestrol.
    Beck PH; McAnich JW; Goebel JL; Stutzman RE
    Urology; 1978 Feb; 11(2):157-60. PubMed ID: 628992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Pregnancy zone" protein in sera from patients with prostatic cancer treated with oestrogens.
    Beckman L; von Schoultz B; Stigbrand T
    Urol Res; 1973 May; 1(2):67-9. PubMed ID: 4130088
    [No Abstract]   [Full Text] [Related]  

  • 25. Carcinoma of prostate: response of plasma luteinizing hormone and testosterone to oestrogen therapy.
    Alder A; Burger H; Davis J; Dulmanis A; Hudson B; Sarfaty G; Straffon W
    Br Med J; 1968 Jan; 1(5583):28-30. PubMed ID: 5636740
    [No Abstract]   [Full Text] [Related]  

  • 26. Radioimmunoassay of diethylstilbestrol in plasma of patients with prostatic carcinoma.
    Usui T; Nakamura K; Osumi T; Ishibe T; Kitano T; Kambegawa A; Miyachi Y
    Arch Androl; 1984; 12(2-3):243-9. PubMed ID: 6508431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasma concentrations of fosfestrol as well as diethylstilbestrol on their conjugates following intravenous administration on prostatic carcinoma patients].
    Oelschläger H; Rothley D; Dunzendorfer U
    Arzneimittelforschung; 1986 Aug; 36(8):1284-9. PubMed ID: 3778569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Orchidectomy and oestrogen therapy of carcinoma of the prostate (author's transl)].
    Straube W; Braun JS
    Urologe A; 1974 Jul; 13(4 Pt A):198-201. PubMed ID: 4137442
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Koontz WW; Prout GR
    Invest Urol; 1972 Mar; 9(5):423-5. PubMed ID: 5016026
    [No Abstract]   [Full Text] [Related]  

  • 31. The adrenal cortex and prostatic cancer.
    Peeling WB; Griffiths K
    Proc R Soc Med; 1974 Nov; 67(11):1156-8. PubMed ID: 4438298
    [No Abstract]   [Full Text] [Related]  

  • 32. [Prolactin and cancer of the prostate (III). Changes in plasma prolactin and testosterone after hormone treatment in prostatic cancer].
    Maganto Pavón E; Mateos Torres JA; Mayayo Dehesa T; Allona Almagro A; Boronat Tormo F; Escudero Barrilero A
    Arch Esp Urol; 1982; 35(4):222-33. PubMed ID: 7138091
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin) in prostatic cancer patients.
    Stege R; Gunnarsson PO; Johansson CJ; Olsson P; Pousette A; Carlström K
    Prostate; 1996 May; 28(5):307-10. PubMed ID: 8610057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Role of hormonal profile in adjusting therapy for prostate cancer].
    Granov AM; Molchanov OE; Karelin MI
    Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Behavior of plasminogen in prostatic carcinoma treated with cytonal].
    Oehler D; Kätzel R; Brunner HP
    Z Urol Nephrol; 1980 Dec; 73(12):923-9. PubMed ID: 6452764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.
    Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD
    Urology; 1996 Jun; 47(6):882-4. PubMed ID: 8677581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prostatic cancer and its prognosis under Honvan treatment].
    Gaca A; Köhnlein HE; Köttgen H
    Med Welt; 1968 Apr; 15():961-7. PubMed ID: 5717752
    [No Abstract]   [Full Text] [Related]  

  • 40. Medical castration with megestrol acetate and minidose of diethylstilbestrol.
    Geller J; Albert J; Yen SS; Geller S; Loza D
    Urology; 1981 Apr; 17(4 Suppl):27-33. PubMed ID: 6782738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.